Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives

被引:0
|
作者
Hartmut Derendorf
Bernd Meibohm
机构
[1] University of Florida,Department of Pharmaceutics, College of Pharmacy
[2] University of South Carolina,Department of Basic Pharmaceutical Sciences, College of Pharmacy
来源
Pharmaceutical Research | 1999年 / 16卷
关键词
pharmacokinetics; pharmacodynamics; pharmacology; modeling;
D O I
暂无
中图分类号
学科分类号
摘要
Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen. PK/PD-modeling approaches can basically be distinguished by four major attributes. The first characterizes the link between measured drug concentration and the response system, direct link versus indirect link. The second considers how the response system relates effect site concentration to the observed outcome, direct versus indirect response. The third regards what clinically or experimentally assessed information is used to establish the link between concentration and effect, hard link versus soft link. And the fourth considers the time dependency of pharmacodynamic model parameters, distinguishing between time-variant versus time-invariant. Application of PK/PD-modeling concepts has been identified as potentially beneficial in all phases of preclinical and clinical drug development. Although today predominantly limited to research, broader application of PK/PD-concepts in clinical therapy will provide a more rational basis for patient-specific dosage individualization and may thus guide applied pharmacotherapy to a higher level of performance.
引用
收藏
页码:176 / 185
页数:9
相关论文
共 50 条
  • [1] Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
    Derendorf, H
    Meibohm, B
    PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 176 - 185
  • [2] Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling
    Meibohm, B
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (10) : 401 - 413
  • [3] COMBINED PHARMACOKINETIC PHARMACODYNAMIC (PK/PD) MODELING
    COLBURN, WA
    JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (09): : 769 - 771
  • [4] Pharmacokinetic (PK) and pharmacodynamic (PD) relationships for intranasal corticosteroids (INCS)
    Daley-Yates, PT
    Richards, DH
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S313 - S313
  • [5] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
  • [6] METHADONE INFUSIONS - PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    MAX, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 211 - 211
  • [7] Pharmacokinetic/pharmacodynamic (PK/PD) modeling of captopril in healthy volunteers.
    Yi, SY
    Bae, KS
    Lim, HS
    Cho, JY
    Yu, KS
    Jang, IJ
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P74 - P74
  • [8] Translational pharmacokinetic (PK), pharmacodynamic (PD) modeling and simulation analysis of MetMAb
    Bender, B.
    Xiang, H.
    Reyes, A. E., II
    Damico, L. A.
    Merchant, M.
    Peterson, A.
    Forrest, W.
    Jumbe, N. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 170 - 170
  • [10] In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
    Xia Xiao
    Jian Sun
    Yi Chen
    Rui-Juan Huang
    Ting Huang
    Guilin Gary Qiao
    Yu-Feng Zhou
    Ya-Hong Liu
    BMC Veterinary Research, 11